Cargando…
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
Ofatumumab (Kesimpta(®)) is a fully human anti-CD20 monoclonal antibody that can be self-administered by patients and is approved in several countries worldwide for the treatment of relapsing forms of multiple sclerosis (MS). In two identical phase III trials in adults with relapsing forms of MS, su...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748350/ https://www.ncbi.nlm.nih.gov/pubmed/34897575 http://dx.doi.org/10.1007/s40265-021-01650-7 |